Lexology November 9, 2022
Baker & Hostetler LLP

Key Takeaways

In response to the COVID-19 pandemic, the White House Office of Science & Technology Policy and the Office of the National Coordinator for Health Information Technology take a major step towards testing interoperability capabilities in clinical trials. The regulatory and technological framework for the interoperability of Electronic Health Records platforms could be applied to the clinical trials context. Shift towards the use of interoperable technologies could improve the collection and exchange of clinical trials data between institutions in emergent and non-emergent settings.

In response to the COVID-19 pandemic, the Biden administration recently announced its National Biodefense Strategy aimed at national preparedness for biological threats. The National Biodefense Strategy sets several targets for improved capabilities in order to respond...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: ASTP/ONC, Biotechnology, Clinical Trials, Govt Agencies, Health IT, HIE (Interoperability), Pharma, Pharma / Biotech, Technology, Trends
Pregnant People Can Freely Make Decisions About Participation In Clinical Research
InnovationRx: Positive Clinical Trial Results For Generative AI-Designed Drug
Copayment Burden Affects Medication Adherence in Chronic Conditions
Neurogene hits a setback in the clinic, days after fundraise
How to adapt to choppy waters in biotech ecosystem

Share This Article